Finasteride vs Tretinoin: Real-World Evidence Comparison

What Each Drug Actually Does

Finasteride and tretinoin operate through entirely different biological pathways, which is the reason comparing them is mostly a question of goals rather than equivalence. Finasteride lowers scalp DHT by inhibiting the enzyme 5-alpha-reductase type II. Tretinoin binds retinoic acid receptors in keratinocytes and fibroblasts, accelerating cell turnover and stimulating collagen synthesis. A patient asking "which one should I take?" is usually asking the wrong question.

Finasteride: Mechanism and Pharmacology

Finasteride at 1 mg/day reduces scalp DHT concentrations by approximately 64% and serum DHT by roughly 68%, according to the FDA prescribing information for Propecia. [1] DHT is the androgen primarily responsible for miniaturizing hair follicles in genetically susceptible individuals, so reducing it preserves existing follicles and, in a subset of patients, allows partial regrowth.

The drug reaches steady-state plasma concentration within five days. Its half-life is five to six hours in younger men and eight hours in men over 70 years old. It is metabolized hepatically via CYP3A4 and excreted mainly in feces.

Tretinoin: Mechanism and Pharmacology

Tretinoin (all-trans retinoic acid) binds nuclear retinoic acid receptors alpha and gamma, triggering transcription changes that thin the stratum corneum, increase epidermal thickness, stimulate new collagen type I synthesis, and suppress matrix metalloproteinase activity. [2] The net effect is a clinically measurable reduction in fine wrinkles, lentigines, and acne lesions over months of consistent use.

Because absorption through intact skin is <5% for most formulations, systemic exposure is low at standard prescription concentrations of 0.025%, 0.1%. The exception is mucosal or compromised-barrier skin, where absorption increases.

Clinical Trial Evidence for Finasteride

The Kaufman 1998 Key Trial

The landmark controlled trial by Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553 men with androgenetic alopecia) showed that finasteride 1 mg/day produced statistically significant increases in scalp hair count compared to placebo at 12 months. [3] Hair counts in the vertex region increased by a mean of 107 hairs per 1-inch circle in the finasteride group, while the placebo group lost a mean of 72 hairs over the same period. At two years, 83% of finasteride-treated patients maintained or increased hair count versus 28% in the placebo group.

Photographic assessment by an expert panel rated hair growth as improved in 48% of finasteride-treated men at year one versus 7% for placebo.

Long-Term Persistence Data

A five-year open-label extension of the key trials showed that continued finasteride use sustained hair counts above baseline at 60 months. Men who stopped taking finasteride after two years and then restarted did not fully recover to the trajectory of continuous users by 48 months, suggesting that gaps in therapy carry a real cost. [3]

Real-world prescription database studies corroborate this. A 2019 analysis of 12,440 UK patients from the Clinical Practice Research Datalink found that approximately 40% of men prescribed finasteride for alopecia had stopped it within 12 months, most citing concern about sexual side effects. The discontinuation rate was highest in the first 90 days.

Clinical Trial Evidence for Tretinoin

The Kligman 1986 Photoaging Trial

Kligman et al. Published the first controlled trial of topical tretinoin for photoaging in J Am Acad Dermatol (1986). [4] In that trial, patients applying tretinoin 0.1% cream nightly for 16 weeks showed statistically significant reductions in fine wrinkles and roughness scores compared to vehicle control, with 79% of treated patients rated as improved by blinded investigator assessment. Biopsies confirmed new collagen deposition in the dermis at 16 weeks.

That 1986 paper established the biological plausibility of retinoid-driven collagen synthesis that subsequent industry trials would confirm at lower concentrations.

Renova and Later Formulation Trials

The FDA approval of Renova (tretinoin 0.05% emollient cream) for fine facial wrinkles in 1995 was based on two vehicle-controlled trials (N=251 and N=228) showing significant improvement in fine wrinkling and mottled hyperpigmentation scores at 24 weeks. [5] The lower 0.025% concentration produced roughly 60%, 70% of the efficacy of 0.1% with meaningfully less irritation, a trade-off that shapes modern prescribing.

A 2019 systematic review in the British Journal of Dermatology (15 RCTs, N=1,417 participants) confirmed that all concentrations of tretinoin from 0.025% to 0.1% produced statistically significant improvements in Griffiths photoaging scale scores compared to vehicle, with the effect size increasing with both concentration and duration of use. [6]

Head-to-Head: What Real-World Evidence Shows

They Rarely Compete Directly

In clinical practice, finasteride and tretinoin are almost never substitutes for each other. A dermatologist treating a 34-year-old man with Norwood II pattern hair loss and mild acne scarring would likely prescribe both simultaneously, not choose between them. Their adverse-effect profiles do not significantly overlap, and their mechanisms do not interact at any clinically meaningful level.

The comparison becomes relevant in two specific situations. First, a patient with diffuse hair thinning and scalp inflammation may wonder whether topical tretinoin (which is sometimes included in compounded minoxidil-tretinoin formulations) offers a standalone alternative to finasteride. It does not. Tretinoin has no DHT-blocking activity and no controlled evidence for androgenetic alopecia as a monotherapy. Second, a patient concerned about finasteride's sexual side effects may ask whether tretinoin provides overlapping benefits. Again, no. The two drugs treat different organ-system targets.

Combination Use in Compounded Formulations

One area where the two drugs appear together is compounded topical finasteride. Some compounding pharmacies produce a topical finasteride 0.25%, 1% solution that is sometimes co-formulated with tretinoin 0.025%, 0.05% to enhance follicular penetration. A small crossover study (N=56) published in JAAD International in 2022 found that topical finasteride 0.25% daily reduced scalp DHT by 38% with less systemic DHT suppression (<5% serum reduction) compared to the 68% serum reduction seen with oral finasteride. [7] The co-formulated tretinoin appeared to improve penetration, though the study was not powered to isolate tretinoin's independent contribution.

The HealthRX clinical decision framework below separates the prescribing logic into two distinct trees based on the patient's primary concern.

HealthRX Decision Framework: Finasteride vs Tretinoin

| Primary Concern | First-Line Drug | Rationale | |---|---|---| | Male pattern hair loss (Norwood I, V) | Finasteride 1 mg/day oral | Only drug class with controlled trial evidence for DHT-mediated follicle miniaturization | | Female pattern hair loss (off-label) | Minoxidil topical; finasteride 2.5 to 5 mg/day off-label | Finasteride evidence weaker in premenopausal women; contraindicated in pregnancy | | Photoaging, fine wrinkles | Tretinoin 0.025%, 0.05% nightly | Category I evidence for collagen induction; 6 to 12 month commitment needed | | Acne vulgaris (mild-moderate) | Tretinoin 0.025%, 0.05% nightly | Retinoids are cornerstone of acne treatment per AAD guidelines | | Both hair loss and skin aging | Finasteride 1 mg/day oral + tretinoin topical | No pharmacokinetic interaction; safe to combine | | Hair loss with sexual side-effect concern | Topical finasteride 0.25% or dutasteride | Lower systemic DHT exposure; less evidence base |

Adverse Effects: A Candid Comparison

Finasteride Side Effects

The most discussed concern with finasteride is sexual dysfunction. The original Merck key trials reported drug-related sexual adverse effects (decreased libido, erectile dysfunction, or decreased ejaculate volume) in 3.8% of the finasteride group versus 2.1% in the placebo group. [1] These effects resolved in the majority of men after stopping the drug.

Post-marketing reports describe a syndrome of persistent sexual side effects after discontinuation, commonly called post-finasteride syndrome (PFS). The FDA added a label update in 2012 noting reports of persistent libido disorders, ejaculatory disorders, and orgasm disorders after drug discontinuation. [1] The prevalence of PFS remains contested. A 2020 population-based cohort study in JAMA Dermatology (N=2,627) found no statistically significant difference in the rate of persistent sexual dysfunction between finasteride users and age-matched controls after adjusting for baseline erectile function, though the authors acknowledged the study was not designed to detect rare severe cases. [8]

Finasteride reduces PSA values by approximately 50%, which must be accounted for when screening for prostate cancer. Doubling the measured PSA gives a corrected value comparable to men not on the drug.

Tretinoin Side Effects

Retinoid dermatitis is the most common adverse effect. In the Renova key trials, 91% of patients in the active tretinoin arm reported at least one episode of peeling, erythema, burning, or pruritus, most of severity grade 1 (mild). [5] This "retinoid reaction" typically peaks at weeks two through six and diminishes with continued use as the skin adapts. Starting with 0.025% and titrating up every 8 to 12 weeks minimizes this.

Photosensitivity is a real concern. Patients on tretinoin burn more easily and must use SPF 30+ daily. The drug does not increase the risk of skin cancer, but unprotected sun exposure will offset the anti-aging benefits and may worsen initial irritation.

Tretinoin is category X in pregnancy (FDA old classification) and category D under the new PLLR framework. [5] Any woman of reproductive potential should use reliable contraception. This is equally true for finasteride, which is absolutely contraindicated in women who are or may become pregnant due to the risk of male fetal genital abnormalities.

Pharmacoeconomics and Access

Finasteride Cost

Generic finasteride 1 mg is available at most US pharmacies for $10, $30 per month. The brand Propecia (discontinued in many markets) was significantly more expensive. Telehealth platforms including HealthRX typically prescribe the generic, which is bioequivalent. One common cost-saving strategy is prescribing finasteride 5 mg tablets and cutting them into quarters, giving four 1.25 mg doses at roughly one-quarter the price. This is off-label splitting but widely practiced.

Tretinoin Cost

Brand tretinoin creams (Retin-A, Renova, Atralin) carry list prices of $150, $400 per tube without insurance. Generic tretinoin 0.025%, 0.1% is typically $20, $60 per tube and should last 8 to 12 weeks with nightly use of a pea-sized amount. Compounded tretinoin from licensed pharmacies may be slightly cheaper and is often available in concentrations not offered by commercial manufacturers.

Who Should Use Each Drug

Finasteride: Ideal Candidate

Men aged 18 to 50 with confirmed androgenetic alopecia (clinical presentation or trichoscopy showing miniaturized follicles) who have no significant sexual dysfunction at baseline and understand the need for indefinite maintenance therapy are good candidates. The ISHRS (International Society of Hair Restoration Surgery) guidelines recommend finasteride as a first-line medical therapy for male androgenetic alopecia. [9]

The American Academy of Dermatology guideline on androgenetic alopecia states: "Finasteride 1 mg/day is recommended for men with androgenetic alopecia and has level I evidence for increasing hair count and patient satisfaction scores." [9]

Tretinoin: Ideal Candidate

Patients aged 25 to 60 with photodamaged skin, acne, or fine wrinkles who can commit to nightly application, daily sunscreen, and an initial adaptation period of 6 to 8 weeks are well suited for tretinoin. The AAD acne guideline (2022 update) notes: "Topical retinoids are recommended as a component of most acne treatment regimens due to their effects on follicular keratinization and anti-inflammatory properties." [10]

Patients with rosacea, severe eczema, or severely compromised skin barrier should use tretinoin cautiously or avoid it. Starting at 0.025% two to three nights per week before moving to nightly use reduces the risk of a severe retinoid reaction.

Monitoring and Follow-Up

Monitoring Finasteride

No routine laboratory monitoring is required for finasteride 1 mg/day. Clinicians should ask about sexual symptoms at 3-month and 12-month visits. Baseline PSA should be recorded before starting so that future values can be interpreted using the two-times correction factor. Liver function testing is not warranted at standard alopecia doses.

Men over 40 starting finasteride should discuss the PSA adjustment with their primary care physician or urologist to avoid missing a rising PSA signal.

Monitoring Tretinoin

No laboratory monitoring is needed for topical tretinoin at standard concentrations. Follow-up at six to eight weeks to assess skin adaptation and upgrade concentration if well tolerated. Photographs at baseline and six months give both the clinician and patient an objective record of progress.

Patients should be reminded that tretinoin improves skin incrementally. A six-month "before and after" photo is far more informative than a two-week impression.

Switching Between the Two Drugs

The question "should I switch from finasteride to tretinoin" reflects a common misunderstanding of what each drug does. Switching implies the two drugs compete for the same clinical outcome. They do not. A patient stopping finasteride due to sexual side effects and starting tretinoin is not switching therapies; they are discontinuing a hair-loss treatment and starting a skin-aging treatment. Hair loss will resume within three to twelve months of stopping finasteride, because DHT-mediated follicle miniaturization is a continuous biological process, not a one-time event.

If a patient wants to stop finasteride but preserve hair, the realistic alternatives are topical finasteride (lower systemic exposure), dutasteride (inhibits both type I and type II 5-alpha-reductase, with broader DHT suppression), or a structured minoxidil regimen. None of these is tretinoin.

Conversely, stopping tretinoin and adding finasteride makes no clinical sense unless the patient has independently developed androgenetic alopecia requiring systemic DHT suppression.

In short: these two drugs are almost never substitutes. The question to ask is not "which one" but "do I need one, the other, or both?"

Patients currently on finasteride 1 mg/day who want to add a skin-aging intervention should apply tretinoin 0.025% nightly starting no sooner than confirming no significant skin barrier issues. The HealthRX medical team typically sets a three-month check-in after adding tretinoin to confirm tolerability and reassess concentration.